Lincoln Pharmaceuticals Limited reported a consolidated net profit of ₹36.23 crore for the quarter ended June 30, 2026, representing a 30.90% increase compared to ₹27.68 crore in the corresponding period of FY26. The Ahmedabad-based pharmaceutical company also saw its total income rise 19.02% to ₹201.55 crore, driven by robust performance across key therapeutic segments including cardiac, diabetic, dermatology, and ENT.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 13, 2026. The results were reviewed by Samir M. Shah & Associates, Chartered Accountants, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial performance

Revenue from operations stood at ₹177.28 crore for the quarter, up from ₹154.07 crore in Q1FY26. EBITDA expanded 32.29% to ₹51.70 crore, outpacing revenue growth and indicating improved operational leverage. Profit before tax rose 34.36% to ₹47.55 crore.

Earnings per share rose to ₹18.09 from ₹13.82 in Q1FY26. For the full fiscal year FY26, the company had reported a net profit of ₹87.89 crore, a 6.74% growth over FY25.

What the numbers show

EBITDA grew at a faster pace than total income in Q1FY27, expanding 32.29% against a 19.02% rise in topline figures. This divergence points to effective cost management or a favorable product mix shift during the quarter, enhancing operating margins despite moderate revenue acceleration.

Strategic outlook

Lincoln Pharmaceuticals remains net-debt free and plans to achieve annual revenue growth of 15-18%, targeting ₹1,000 crore in revenue over the next three years. The company plans to expand its export footprint from over 60 countries to 90 countries within two to three years, leveraging recent approvals from EU GMP, TGA Australia, and entry into the Canadian market.

CRISIL Ratings has reaffirmed its 'CRISIL A/Stable/CRISIL A1' ratings on the company's bank facilities, citing strong promoter experience and a healthy financial profile. Foreign Institutional Investors held a stake of 4.60% as on June 30, 2026.

Lincoln Pharmaceuticals reported a strong start to the fiscal year, with standalone net profit rising 31% year-on-year to ₹362 crore in the first quarter. This compares to a profit of ₹277 crore in the corresponding period last year.

The company’s revenue also expanded, logging ₹1.77 billion for the quarter against ₹1.54 billion in the previous year. This represents a 15% growth in top-line figures, indicating sustained demand across its product portfolio.

Financial Performance

Operating profitability remained resilient during the period. Lincoln Pharmaceuticals posted an EBITDA of ₹273 million, up from ₹238 million in the prior year. The EBITDA margin was maintained at 15.5%, identical to the figure recorded in the same quarter last year, suggesting effective cost management despite the revenue expansion.

What the Numbers Show

A key observation from the filing is the divergence between operating and bottom-line growth. While EBITDA grew by approximately 15%, net profit surged by 31%. This acceleration in bottom-line performance relative to operating profits suggests that factors beyond core operations—such as other income or favorable tax adjustments—contributed significantly to the higher net profit figure, as the operating margin remained unchanged.